Von Willebrand Factor/ADAMTS13 Ratio at Presentation of Acute Ischemic Brain Injury is Predictive of Outcome

Overview

Journal Blood Adv

Specialty Hematology

Date 2020 Jan 29

PMID 31990334

Citations 15

Authors

Alice Taylor

Chiara Vendramin

Deepak Singh

Martin M Brown

Marie Scully

Affiliations

Soon will be listed here.

Abstract

Acute ischemic stroke (IS) and transient ischemic attack (TIA) are associated with raised von Willebrand factor (VWF) and decreased ADAMTS13 activity (ADAMTS13Ac). Their impact on mortality and morbidity is unclear. We conducted a prospective investigation of the VWF-ADAMTS13 axis in 292 adults (acute IS, n = 103; TIA, n = 80; controls, n = 109) serially from presentation until >6 weeks. The National Institutes of Health Stroke Score (NIHSS) and modified Rankin scale (mRS) were used to assess stroke severity. Presenting median VWF antigen (VWF:Ag)/ADAMTS13Ac ratios were: IS, 2.42 (range, 0.78-9.53); TIA, 1.89 (range, 0.41-8.14); and controls, 1.69 (range, 0.25-15.63). Longitudinally, the median VWF:Ag/ADAMTS13Ac ratio decreased (IS, 2.42 to 1.66; P = .0008; TIA, 1.89 to 0.65; P < .0001). The VWF:Ag/ADAMTS13Ac ratio was higher at presentation in IS patients who died (3.683 vs 2.014; P < .0001). A presenting VWF:Ag/ADAMTS13Ac ratio >2.6 predicted mortality (odds ratio, 6.33; range, 2.22-18.1). Those with a VWF:Ag/ADAMTS13Ac ratio in the highest quartile (>3.091) had 31% increased risk mortality. VWF:Ag/ADAMTS13Ac ratio at presentation of ischemic brain injury was associated with higher mRS (P = .021) and NIHSS scores (P = .029) at follow-up. Thrombolysis resulted in prompt reduction of the VWF:Ag/ADAMTS13Ac ratio and significant improvement in mRS on follow-up. A raised VWF:Ag/ADAMTS13Ac ratio at presentation of acute IS or TIA is associated with increased mortality and poorer functional outcome. A ratio of 2.6 seems to differentiate outcome. Prompt reduction in the ratio in thrombolysed patients was associated with decreased mortality and morbidity. The VWF:Ag/ADAMTS13Ac ratio is a biomarker for the acute impact of an ischemic event and longer-term outcome.

Citing Articles

The Role of the VWF/ADAMTS13 Axis in the Thromboinflammatory Response in Ischemic Stroke After SARS-CoV2 Infection.

Luka N, South K, Jones R, Unsworth A, Coutts G, Mosneag I Brain Behav. 2025; 15(2):e70348.

PMID: 39972966 PMC: 11839761. DOI: 10.1002/brb3.70348.

Injury-induced endotheliopathy: What you need to know.

Cardenas J, Dong J, Kozar R J Trauma Acute Care Surg. 2023; 95(4):454-463.

PMID: 37314417 PMC: 10527751. DOI: 10.1097/TA.0000000000004082.

ADAMTS13 Activity Measurement by ELISA and Fluorescence Resonance Energy Transfer Assay.

Moore G, Llusa M, Griffiths M, Binder N Methods Mol Biol. 2023; 2663:533-547.

PMID: 37204735 DOI: 10.1007/978-1-0716-3175-1_35.

Spatiotemporal profile of neutrophil extracellular trap formation in a mouse model of ischemic stroke.

De Wilde M, Desender L, Tersteeg C, Vanhoorelbeke K, De Meyer S Res Pract Thromb Haemost. 2023; 7(1):100028.

PMID: 36852112 PMC: 9958086. DOI: 10.1016/j.rpth.2022.100028.

Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment.

Lu H, Li S, Zhong X, Huang S, Jiao X, He G BMC Neurol. 2022; 22(1):359.

PMID: 36127663 PMC: 9487126. DOI: 10.1186/s12883-022-02898-6.

References

Kleinschnitz C, De Meyer S, Schwarz T, Austinat M, Vanhoorelbeke K, Nieswandt B . Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009; 113(15):3600-3. DOI: 10.1182/blood-2008-09-180695. View

Andersson H, Siegerink B, Luken B, Crawley J, Algra A, Lane D . High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2011; 119(6):1555-60. DOI: 10.1182/blood-2011-09-380618. View

Nakano T, Irie K, Hayakawa K, Sano K, Nakamura Y, Tanaka M . Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication. Brain Res. 2015; 1624:330-335. DOI: 10.1016/j.brainres.2015.07.027. View

Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T . FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005; 129(1):93-100. DOI: 10.1111/j.1365-2141.2005.05420.x. View

Sonneveld M, de Maat M, Portegies M, Kavousi M, Hofman A, Turecek P . Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 2015; 126(25):2739-46. DOI: 10.1182/blood-2015-05-643338. View

Quinn T, Dawson J, Walters M . Dr John Rankin; his life, legacy and the 50th anniversary of the Rankin Stroke Scale. Scott Med J. 2008; 53(1):44-7. DOI: 10.1258/RSMSMJ.53.1.44. View

Denorme F, De Meyer S . The VWF-GPIb axis in ischaemic stroke: lessons from animal models. Thromb Haemost. 2016; 116(4):597-604. DOI: 10.1160/TH16-01-0036. View

. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24):1581-7. DOI: 10.1056/NEJM199512143332401. View

Qu L, Jiang M, Qiu W, Lu S, Zhao Y, Xia L . Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction. Clin Appl Thromb Hemost. 2015; 22(3):252-9. DOI: 10.1177/1076029615583347. View

10.

Penz S, Reininger A, Toth O, Deckmyn H, Brandl R, Siess W . Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost. 2007; 97(3):435-43. View

11.

Adams Jr H, Bendixen B, Kappelle L, Biller J, Love B, Gordon D . Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24(1):35-41. DOI: 10.1161/01.str.24.1.35. View

12.

Chauhan A, Motto D, Lamb C, Bergmeier W, Dockal M, Plaimauer B . Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006; 203(3):767-76. PMC: 2118248. DOI: 10.1084/jem.20051732. View

13.

Fujioka M, Hayakawa K, Mishima K, Kunizawa A, Irie K, Higuchi S . ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood. 2009; 115(8):1650-3. DOI: 10.1182/blood-2009-06-230110. View

14.

Brown M . New national guideline for stroke management: where do we go from here?. Clin Med (Lond). 2012; 12(5):407-9. PMC: 4953759. DOI: 10.7861/clinmedicine.12-5-407. View

15.

Wieberdink R, van Schie M, Koudstaal P, Hofman A, Witteman J, de Maat M . High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010; 41(10):2151-6. DOI: 10.1161/STROKEAHA.110.586289. View

16.

Shida Y, Nishio K, Sugimoto M, Mizuno T, Hamada M, Kato S . Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood. 2007; 111(3):1295-8. DOI: 10.1182/blood-2007-09-110700. View

17.

Green D, Tian L, Greenland P, Liu K, Kibbe M, Tracy R . Association of the von Willebrand Factor-ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease. Clin Appl Thromb Hemost. 2016; 23(7):807-813. PMC: 6689399. DOI: 10.1177/1076029616655615. View

18.

Lambers M, Goldenberg N, Kenet G, Kirkham F, Manner D, Bernard T . Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study. Ann Neurol. 2012; 73(1):58-64. PMC: 3703929. DOI: 10.1002/ana.23735. View

19.

Ruggeri Z . Platelets in atherothrombosis. Nat Med. 2002; 8(11):1227-34. DOI: 10.1038/nm1102-1227. View

20.

Wannamethee S, Whincup P, Lennon L, Rumley A, Lowe G . Fibrin D-dimer, tissue-type plasminogen activator, von Willebrand factor, and risk of incident stroke in older men. Stroke. 2012; 43(5):1206-11. DOI: 10.1161/STROKEAHA.111.636373. View